VYNE Therapeutics (VYNE) Insider Trading & Ownership $2.72 -0.01 (-0.37%) (As of 10/31/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE Therapeutics (NASDAQ:VYNE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$50,830.00Number OfInsiders Selling(Last 12 Months)0 Get VYNE Insider Trade Alerts Want to know when executives and insiders are buying or selling VYNE Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VYNE Insider Buying and Selling by Quarter Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… VYNE Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/15/2023Patrick G LeporeDirectorBuy13,000$3.91$50,830.00 (Data available from 1/1/2013 forward) VYNE Insider Trading Activity - Frequently Asked Questions Who is on VYNE Therapeutics's Insider Roster? The list of insiders at VYNE Therapeutics includes Mutya Harsch, and Patrick G Lepore. Learn more on insiders at VYNE. What percentage of VYNE Therapeutics stock is owned by insiders? 1.80% of VYNE Therapeutics stock is owned by insiders. Learn more on VYNE's insider holdings. Which VYNE Therapeutics insiders have been buying company stock? The following insiders have purchased VYNE shares in the last 24 months: Mutya Harsch ($25,000.00), and Patrick G Lepore ($100,430.00). How much insider buying is happening at VYNE Therapeutics? Insiders have purchased a total of 43,000 VYNE shares in the last 24 months for a total of $125,430.00 bought. VYNE Therapeutics Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Compensation: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Compensation: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Compensation: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel FAAD (Age 73)M.D., Consultant Compensation: $40.2k More Insider Trading Tools from MarketBeat Related Companies HOOK Insider Trading KZR Insider Trading VTYX Insider Trading SKYE Insider Trading SCPH Insider Trading TNYA Insider Trading RPTX Insider Trading FTLF Insider Trading VXRT Insider Trading PBYI Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:VYNE) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
